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Background: Central lineeassociated bloodstream infections (CLABSIs) result in increased length of stay,
cost, and patient morbidity and mortality. One CLABSI prevention method is disinfection of intravenous
access points. The literature suggests that placing disinfectant caps over needleless connectors decreases
CLABSI risk.
Methods: A quasi-experimental intervention study was conducted in a >430-bed trauma I center. In
addition to an existing standard central line bundle, a new intervention consisting of a luer-lock disinfectant cap with 70% alcohol was implemented in all intravenous (IV) needleless connectors on patients
with peripheral and central lines. Compliance to the disinfectant cap was monitored weekly. A generalized linear model using a Poisson distribution was ﬁt to determine if there were signiﬁcant relationships between CLABSIs and disinfectant cap use. Impacts on costs were also examined.
Results: The rate of CLABSI decreased following implementation of the disinfectant cap. The incidence
rate ratios (.577, P ¼ .004) for implementing the disinfectant caps was statistically signiﬁcant, indicating
that the rate of patient infections decreased by >40%. Increased compliance rates were associated with
lower infection rates. Disinfectant cap use was associated with an estimated savings of almost $300,000
per year in the hospital studied.
Conclusions: Use of a disinfectant cap on IV needleless connectors in addition to an existing standard
central line bundle was associated with decreased CLABSI and costs.
Copyright Ó 2014 by the Association for Professionals in Infection Control and Epidemiology, Inc.
Published by Elsevier Inc. All rights reserved.

The magnitude of central lineeassociated bloodstream infections (CLABSIs) in the United States and abroad is staggering. It is
estimated that 200,000-400,000 episodes of bloodstream infections occur annually in U.S. hospitals, resulting in increased
length of stay, cost, and patient morbidity and mortality.1 Nearly 1
in every 10 hemodialysis catheters fail each month as a result of
CLABSI, and the numbers are even greater in nontunneled catheters
used in the acute care setting. Researchers report that mortality
rates are between 12% and 25% from CLABSIs and estimate that
annual costs associated with treatment exceed $2 billion.2,3
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The goal of hospital infection prevention programs is to eliminate CLABSI or decrease it as much as feasible given the patient
population.3 Methods to reduce CLABSI consist of implementing
several techniques referred to as a bundle of interventions that
specify recommendations for proper insertion and appropriate
handling of central lines.4 These multimodal approaches have been
successful in decreasing CLABSI.5,6
One speciﬁc aspect of the central line bundle is to minimize
infection from intravenous (IV) access points. Most IV tubing contains several needleless connectors for the purposes of medication
delivery and blood draws. Nurses access these needleless connectors several times a day, potentially increasing the possibility of
contamination and subsequent infection.
To prevent infection in patients with IV access devices, the
Centers for Disease Control and Prevention strongly recommend
appropriate disinfectant of needleless connectors prior to access.3
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Fig 1. Effect of disinfectant cap on CLABSI rate. CLABSI, central lineeassociated bloodstream infection.

Although time and friction are recommended for disinfection, there
are no speciﬁc recommendations on the amount of time needed to
reach optimal disinfection (eg, 10, 15, or 30 seconds). Additionally,
some argue that proper disinfection practices are difﬁcult to
maintain given the increased work load of nurses.7
In a 2006 in vitro study, researchers reported that the use of 70%
alcohol prior to needleless connector entry is not sufﬁcient protection against microbial contamination; therefore, the use of a
disinfectant cap was recommended.8 The literature suggests that a
disinfectant cap placed over IV needleless connectors decreases
colonization on the connector, therefore lowering the risk of
CLABSI.9 Another quality improvement study found that the use of
a closed luer-lock disinfectant cap signiﬁcantly decreased hemodialysis catheter infections in pediatric patients.10 In a more recent
study, the implementation of a disinfectant cap decreased line
contamination, bacterial density, and CLABSI rates.11 Based on these
promising results, additional research is needed to test the generalizable effectiveness of widespread implementation of a disinfectant cap to decrease or eliminate CLABSI.
The purpose of this study is to analyze the effect of universal IV
needleless connector disinfectant cap implementation on the rate
and type of CLABI and estimated costs in a large tertiary care
center using a standard central line bundle. Additionally, the
relationship between disinfectant cap compliance and CLABSI
rates is explored.

patients in the emergency department, ambulatory care, surgical
services, labor and delivery, and well-baby nursery and patients
who were postpartum.

Intervention
The disinfectant cap (Curos Disinfecting Port Protector, Curos,
San Diego, CA) is a plastic-threaded device that contains 70%
isopropyl alcohol. This device received a 510(k) clearance from the
U.S. Food and Drug Administration for 1-time use.13 It is effective
within 3 minutes of application and may be used up to 7 days.
Prior to implementation, the hospital product review committee
and the institutional review board approved the use of the
product for this research study. Nursing staff were introduced to
the proper use of the cap through onsite training by the vendor, an
education fact sheet, or required online training. Staff also
participated in individual 1-on-1 follow up.
In this study, the disinfectant cap was placed universally on all
IV needleless connectors (central, peripheral, and IV tubing) when
the connectors were not in use. Compliance to the disinfectant cap
was monitored weekly and reported to each unit to encourage use
of the disinfectant cap.

Data collection and analysis
METHODS
Setting and design
This quasi-experimental short interrupted time series12 intervention study was conducted in a 430-bed tertiary care trauma I
center in the U.S. Mountain West. A luer-lock disinfectant cap with
70% alcohol was implemented in all patients (newborn to adults)
with peripheral and central lines residing on 13 inpatient units at 1
hospital beginning in January 2012. Excluded from this study were

Compliance
Following implementation of the disinfectant cap, compliance
was determined by audits conducted 1-2 times per week beginning
in February 2012 and lasting throughout the study period. The
number of disinfectant caps present was divided by the number of
total available needleless connectors to result in an overall
compliance rate per central line patient. The data were then
aggregated to the nursing department level and reported to each
manager as a weekly nursing department compliance rate.
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Table 1
Disinfectant cap intervention, CLABSI rates, and compliance parameter estimates
Model
CLABSI
Intervention
CLABSI
Compliance

Parameter

B

Intercept
2.161
Intervention ¼ 1 0.55
Intercept
2.19
Compliance %
0.073

SE

P

IRR

95% CI for IRR

0.073
0.193
0.0877
0.0228

.000*
.004*
.000*
.001*

0.115
0.577
0.112
0.93

.100-.133
.396-.842
.094-.133
.889-.972

CI, conﬁdence interval; CLABSI, central lineeassociated bloodstream infection; IRR,
incidence rate ratio.
*Statistically signiﬁcant result.

Table 2
Effect of disinfectant cap on central lineeassociated bloodstream infection costs

Item
Supplies
Annual BSI cost
(estimated at
$25,000 per
episode)
Totals

Estimated costs in
2011 (before
implementation)

Estimated costs in
2012 (following
implementation)

Estimated cost
avoidance

NA
$1,050,000

$192,160
$575,000

$(192,160)
$475,000

$1,050,000

$575,000

$282,840

BSI, bloodstream infection; NA, not applicable.

CLABSI
The presence of CLABSI was deﬁned as “a primary laboratory
conﬁrmed bloodstream infection in a patient with a central line at
the time of (or within 48 hours prior to) the onset of symptoms and
the infection is not related to an infection from another site.”3 All
positive blood cultures in the hospital were reviewed to determine
if they met the deﬁnition for CLABSI. The rate of CLABSI was
calculated per 1,000 central line catheter days.
Impact of CLABSI
Cost, estimated case fatality, and additional ICU length of stay
were estimated to represent the impact of CLABSI. Cost of CLABSI
was estimated at $25,000 per case, a low estimate based on the
literature, which estimates CLABSI results at $25,000-$55,000 per
incident.2,14 Estimated case fatality was based as 6%, with 4 additional days in the hospital; both are low estimates from the CDC
literature.2,14 The number of CLABSI cases was multiplied by the
estimated cost, mortality, and length of stay before and after
implementation of the disinfectant cap. The cost of implementation
supplies (disinfectant cap and no-port tubing) were also taken into
consideration.
Analysis
The rate of CLABSI and costs were compared for 12 months
before (2011) and after the intervention (2012). Data were analyzed
using IBM SPSS version 22.0 (SPSS Inc, Chicago, IL).15 A generalized
linear model using a Poisson distribution was ﬁt to determine if
there was a signiﬁcant difference in CLABSI rates following implementation of the disinfectant cap. The model was adjusted for the
number of line days per patient.
RESULTS
The rate of CLABSI per 1,000 central line days decreased
following implementation of the disinfectant cap (before implementation: mean  SD, 1.5  .37) (after implementation: mean 
SD, .88  .62) (Fig 1). The robust estimator option was used as the
deviance statistic (.679) and was somewhat <1 as assumed when
using the Poisson distribution.16 The incidence rate ratio
(IRR ¼ .577, P ¼ .004) for implementing the disinfectant caps was
statistically signiﬁcant, indicating that the rate of patient infections
decreased by >40% with the use of the disinfectant cap. Parameter
estimates are reported in Table 1.
Before implementation (2011), the total estimated cost for
CLABSI for the hospital in this study was $1 million per year.
Following implementation of the disinfectant cap (2012), the cost
of CLABSI was estimated at $575,000 per year. After subtracting the
cost of supplies, this resulted in an estimated annual savings of
$282,840 (Table 2). We also estimated that implementation of the
disinfectant cap resulted in a decrease of 68 patient hospital days
and prevented one death.

DISCUSSION
CLABSI is a signiﬁcant health careeacquired infection; however,
CLABSI is preventable. Improvement efforts were successful by
creating a feedback loop to improve practice and foster innovation.
Nurses received compliance reports from infection preventionists,
which resulted in increased compliance. A notable ﬁnding in this
study is that a 10% increase in compliance resulted in a 7% drop in
infection (IRR ¼ .93; 95% conﬁdence interval, .889-.972), as seen in
Table 1. In addition, during implementation, nurses expressed
frustration that uncovered needleless connectors high in the IV
tubing that were never used were counted against compliance
rates. As a result of this feedback, the hospital purchased no-port
tubing, further protecting the patient from potential entries into
the system. Creating a feedback loop proved to be an important
strategy for increasing compliance, thereby preventing infection as
is supported by the quality improvement plan-do-check-act cycle.17
Another important ﬁnding in this study is the relationship with
implementation of a disinfectant cap and a signiﬁcant decrease in
CLABSI rates. These ﬁndings are timely because they support the
growing body of knowledge that disinfectant caps are one method
to prevent CLABSI.8,11,18 This study also showed that disinfectant
caps are one aspect of aseptic techniques for preventing CLABSI that
is easier to monitor for compliance than other infrequent procedures (eg, dressing change, line insertion) that are not readily
apparent with visual surveillance.
The treatment of CLABSI varies by patient; however, most clinicians agree that CLABSI results in an increased hospital length of
stay and, in some cases, death. This study used low estimations for
length of stay and mortality; even so, implementation of the
disinfectant cap might have decreased hospital stays by 1 day per
week and eliminated 1 death during the study period. Using the
CLABSI opportunity estimator published by Johns Hopkins Quality
Safety Research Group would have doubled these numbers.19
Although improved patient outcomes alone should be a sufﬁcient motivator to prevent health careeacquired infections, it is
often the ﬁnancial impact that receives the most attention. In a
comparative study, the costs of hospitalized patients who acquired
CLABSI were matched with similar patients who did not experience
CLABSI. They concluded that the occurrence of CLABSI resulted in a
signiﬁcant impact on hospital operating costs.6
When infections are prevented, the impact is calculated in terms
of cost avoidance. After considering the costs of purchasing disinfectant caps and no-port tubing, this current study also identiﬁed a
signiﬁcant cost avoidance by decreasing CLABSI. Cost avoidance is
considered soft money and can be difﬁcult to track and justify. It is
important to emphasize cost avoidance when considering the investment in the purchase of disinfectant caps and no-port tubing.
This study was successful in part because of the support of hospital
administration and the cooperation of the hospital products committee who understood the overall patient safety ramiﬁcations and
cost savings.
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Disinfection of the IV needleless connectors is only one aspect of
CLABSI prevention. Other aspects of prevention (eg, insertion,
dressing changes) are important to consider for those striving for
zero infection rates. Unfortunately, compliance to these important
aseptic techniques might be more difﬁcult to measure than
compliance to a disinfectant cap.
LIMITATIONS
There are some limitations to this study. Ongoing education was
implemented simultaneously by the hospital, which might have
affected the CLABSI rates. Further, use of the disinfectant cap may
have resulted in an increased vigilance to compliance to the central
line bundle, which was not measured as part of the study. Cost
estimates were based on projections reported in the literature.
Although costs were about 50% lower than other reports, they
might not reﬂect true costs.
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CONCLUSION
11.

CLABSI is a serious, preventable, health careeacquired infection.
This study found a relationship between implementation of a
disinfectant cap and reduced rates of CLABSI, cost, length of stay,
and mortality. As this increasing body of knowledge becomes
available, infection preventionists might need to consider that
some time honored traditions (eg, scrub the hub) should now be
replaced with new product technology. Further, this study found
success in implementation of a quality improvement feedback loop
and found that compliance rates resulted in prevention of CLABSI.
This improvement model might prove successful in other infection
prevention campaigns.
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